| Market Cap | ₹126.19 CrSmall Cap |
|---|---|
| Revenue Annual | ₹110.02 CrFY26 Operating |
| P/E Ratio | 10.73Sector 43.36 |
| Deal value | ₹14.53 Cr |
| Share of market cap | 11.5% |
| Share of annual revenue | 13.2% |
Key highlights
- Finalised a commercial transaction for the Blueberry project worth ₹14.53 crore
- Scope includes the provision of infrastructure and specialised growing systems
- Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015
- The transaction value represents approximately 13.2% of the company's annual operating revenue
- Project aligns with the company's strategy to expand its agro-technology and turnkey solutions portfolio
What Is the Order?
Sheel Biotech Limited has finalised a commercial transaction valued at ₹14.53 crore specifically for its Blueberry project. The engagement involves providing the necessary infrastructure and high-tech growing systems required for large-scale blueberry cultivation. This development, disclosed to the National Stock Exchange on September 10, 2026, falls under the company's turnkey project segment.
The project aims to implement advanced agricultural setups that support precision farming, ensuring optimal growth conditions for blueberries, which are increasingly sought after in the domestic and international markets for their high economic value and health benefits.
Business Impact
The finalisation of this ₹14.53 crore transaction provides significant revenue visibility for Sheel Biotech. Given the company's annual operating revenue of ₹110.02 crore, this single project contributes substantially to its top-line growth. Beyond the immediate financial gain, the contract reinforces the company's technical expertise in the niche berry cultivation segment.
Successfully delivering this turnkey infrastructure could position the company for higher-value domestic contracts as India shifts towards high-density, tech-enabled farming. The project also leverages the company's existing tissue culture and greenhouse capabilities, potentially improving overall margins through integrated project execution.
Business Overview
- Specialises in biotechnology, floriculture, greenhouse construction, and organic farming
- Operates advanced tissue culture laboratories with a production capacity of 10 million plants annually
- Provides turnkey agricultural solutions including mist chambers and phytotron facilities
- Manages over 50 Farmer Producer Organizations (FPOs) across multiple Indian states
- Maintains global partnerships for patented genetics and advanced climatic equipment
Financial Context
Sheel Biotech currently maintains a market capitalisation of ₹126.19 crore and is trading at a P/E ratio of 10.73, which is significantly lower than the industry average of 25.81 and the sector P/E of 43.36. The company reported a net profit of ₹11.76 crore for the most recent annual period, achieving a profit growth of 10.53% year-on-year. While revenue growth stood at 8.28%, the company has a strong promoter holding of 72.29%, indicating a stable ownership structure.
However, the company reported a negative cash flow from operating activities of ₹17.57 crore, highlighting the capital-intensive nature of its infrastructure and turnkey project model.
Industry Landscape
The Indian blueberry market is witnessing a transition from total import dependency to indigenous commercial cultivation. As consumer demand for health-focused superfruits grows in Tier-I cities, the need for specialised agro-infrastructure has escalated. High-tech solutions like polyhouses, irrigation systems, and climatic control are essential for growing blueberries in non-traditional climates.
Sheel Biotech is positioning itself as a primary solution provider in this emerging berry economy. The company's focus on end-to-end execution—from tissue culture plant supply to cold storage planning—addresses critical gaps in the agricultural value chain, aligning with national goals for high-value crop diversification.
| Share price | ₹62 |
|---|---|
| Market capitalisation | ₹126.19 Cr |
| Revenue (annual) | ₹110.02 Cr |
| Net profit (annual) | ₹11.76 Cr |
| P/E (TTM) | 10.73×Sector 43.36× |
| Promoter holding | 72.29% |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Sheel Biotech Limited announcing the finalisation of a ₹14.53 crore transaction for its Blueberry project. Market figures from a third-party data provider.
